These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20875552)

  • 1. Stem cell transplant for chronic myeloid leukemia in the imatinib era.
    Radich J
    Semin Hematol; 2010 Oct; 47(4):354-61. PubMed ID: 20875552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
    Innes AJ; Apperley JF
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.
    Cutler C; Antin JH
    Curr Hematol Malig Rep; 2006 Sep; 1(3):160-7. PubMed ID: 20425347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic myeloid leukemia with imatinib mesylate.
    Ohno R
    Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.
    Jain N; van Besien K
    Hematol Oncol Clin North Am; 2011 Oct; 25(5):1025-48, vi. PubMed ID: 22054733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.
    Muramatsu H; Takahashi Y; Sakaguchi H; Shimada A; Nishio N; Hama A; Doisaki S; Yagasaki H; Matsumoto K; Kato K; Kojima S
    Int J Hematol; 2011 Feb; 93(2):186-191. PubMed ID: 21234820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3. Imatinib therapy in chronic myelogenous leukemia.
    Jinnai I
    Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
    [No Abstract]   [Full Text] [Related]  

  • 9. [Chronic myeloid leukemia 2008].
    Cervantes F
    Med Clin (Barc); 2008 Nov; 131(17):658-9. PubMed ID: 19087793
    [No Abstract]   [Full Text] [Related]  

  • 10. Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.
    Giralt S
    Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S102-4. PubMed ID: 17382018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure.
    O'Connor LM; Langabeer S; McCann SR; Conneally E
    Bone Marrow Transplant; 2008 Dec; 42(12):833-5. PubMed ID: 18711344
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic myelogenous leukemia.
    Mauro MJ; Druker BJ
    Curr Opin Oncol; 2001 Jan; 13(1):3-7. PubMed ID: 11148678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
    Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
    Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic transplant for chronic myeloid leukemia in 2010.
    Radich JP
    Ther Adv Hematol; 2010 Feb; 1(1):5-13. PubMed ID: 23556067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Stem cell transplantation in the imatinib era].
    Masszi T
    Orv Hetil; 2005 May; 146(18 Suppl 1):900-4. PubMed ID: 15921302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
    Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
    Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of chronic myeloid leukemia in childhood.
    Suttorp M; Eckardt L; Tauer JT; Millot F
    Curr Hematol Malig Rep; 2012 Jun; 7(2):116-24. PubMed ID: 22395816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.
    Bar M; Radich J
    J Natl Compr Canc Netw; 2013 Mar; 11(3):308-15. PubMed ID: 23486457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
    Wang Y; Wu D; Sun A; Jin Z; Qiu H; Miao M; Tang X; Fu Z
    Int J Hematol; 2008 Mar; 87(2):167-171. PubMed ID: 18288566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.